<div id="readability-page-1"><p>In a report released today, Albert Lowe from Craig-Hallum reiterated a Buy rating on Lineage Therap, with a price target of <span id="expert-recommendation-target">$3.00</span>.</p><h3>TipRanks Black Friday Sale</h3><ul><li> Claim 60% off TipRanks Premium  for the data-backed insights and research tools you need to invest with confidence.  </li><li>  Subscribe to TipRanks' Smart Investor Picks  and see our data in action through our high-performing model portfolio - <u> now also 60% off </u></li></ul> <p>According to TipRanks, Lowe is a 4-star analyst with an average return of <span>16.5%</span> and a 50.68% success rate. Lowe covers the Healthcare sector, focusing on stocks such as Rezolute, Atossa Therapeutics, and Skye Bioscience.</p> <p>In addition to Craig-Hallum, Lineage Therap also received a Buy from H.C. Wainwright’s Joseph Pantginis in a report issued yesterday. However, on November 13, TR | OpenAI – 4o reiterated a Hold rating on Lineage Therap (NYSE MKT: LCTX).</p></div>

LCTX

<p>Albert Lowe from Craig-Hallum reiterated a Buy rating on Lineage Therap with a price target of $3.00. Lowe is a 4-star analyst with an average return of 16.5% and a 50.68% success rate. Lineage Therap also received a Buy rating from H.C. Wainwright’s Joseph Pantginis, while TR reiterated a Hold rating on November 13.</p>

Lineage Therap (LCTX) Gets a Buy from Craig-Hallum